Patents by Inventor Kiel Lazarski

Kiel Lazarski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
    Publication number: 20250057957
    Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Application
    Filed: July 16, 2024
    Publication date: February 20, 2025
    Applicant: C4 THERAPEUTICS, INC.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael
  • Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancers
    Patent number: 12209091
    Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: January 28, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martin Duplessis, Annick Goergler, Georg Jaeschke, Buelent Kocer, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Ulrike Obst Sander, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
    Publication number: 20240398959
    Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Application
    Filed: April 22, 2024
    Publication date: December 5, 2024
    Applicant: C4 THERAPEUTICS, INC.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
  • Macrocyclic fluorine substituted indole derivatives
    Patent number: 12152041
    Abstract: The present invention relates to macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: November 26, 2024
    Assignees: The Broad Institute, Inc., Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Steven James Ferrara, Michael H. Serrano-Wu, Chris Lemke, David McKinney, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Laura Furst, Guo Wei, Patrick Ryan McCarren, Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Rauh, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Mönning
  • Spirocyclic degronimers for target protein degradation
    Patent number: 12048748
    Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: July 30, 2024
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael
  • Substituted piperidine Degronimers for Target Protein degradation
    Patent number: 12048747
    Abstract: This invention provides amine-linked C3-glutarimide Degronimers for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation, wherein the C3-glutarimide Degronimers have the formula:
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: July 30, 2024
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Chi-Li Chen, Martin Duplessis, Minsheng He, Kiel Lazarski
  • C-carbon linked glutarimide degronimers for target protein degradation
    Patent number: 11992531
    Abstract: This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: May 28, 2024
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Minsheng He, Kiel Lazarski, Gesine Kerstin Veits, Harit U. Vora
  • EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS
    Publication number: 20240158418
    Abstract: The invention provides for the treatment of mutant epidermal growth factor receptor (EGFR) mediated cancer that has metastasized to the brain or other area of the central nervous system with a compound that degrades a mutant form of EGFR via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The invention also provides advantageous drug combinations for the treatment of such cancer that include a compound herein that degrades a mutant form of EGFR in combination with a second anti-cancer agent.
    Type: Application
    Filed: November 21, 2023
    Publication date: May 16, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR
    Publication number: 20240076300
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: May 8, 2023
    Publication date: March 7, 2024
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • Substituted macrocyclic indole derivatives
    Patent number: 11891404
    Abstract: The present invention relates to substituted macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: September 8, 2022
    Date of Patent: February 6, 2024
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.
    Inventors: Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Rauh, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Katrin Nowak-Reppel, Sven Wittrock, David McKinney, Michael H. Serrano-Wu, Chris Lemke, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven James Ferrara, Laura Furst, Guo Wei, Patrick Ryan McCarren, Rebecca Ann Harvey
  • DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION
    Publication number: 20230357180
    Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.
    Type: Application
    Filed: December 12, 2022
    Publication date: November 9, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski
  • COMPOUNDS FOR TARGETED DEGRADATION OF RET
    Publication number: 20230233692
    Abstract: Novel compounds which act as protein degradation inducing moieties for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET.
    Type: Application
    Filed: February 3, 2023
    Publication date: July 27, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: James A. Henderson, Christopher G. Naveschuk, Kiel Lazarski, Victoria Garza, Moses Moustakim, Jae Young Ahn, Gesine Kerstin Veits, Morgan Welzel O'Shea, Ryan E. Michael, Jeremy L. Yap, Yanke Liang, Andrew Charles Good, Mark E. Fitzgerald, Robert T. Yu
  • 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds
    Patent number: 11708354
    Abstract: The present invention provides compounds which are selective allosteric inhibitors of T790M and C797S containing EGFR mutants, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: July 25, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martin Duplessis, Georg Jaeschke, Bernd Kuhn, Kiel Lazarski, Yanke Liang, Yvonne Alice Nagel, Antonio Ricci, Daniel Rueher, Sandra Steiner
  • Isoindolinone and indazole compounds for the degradation of EGFR
    Patent number: 11673902
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Grant
    Filed: June 17, 2022
    Date of Patent: June 13, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR
    Publication number: 20230110648
    Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
    Type: Application
    Filed: June 17, 2022
    Publication date: April 13, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Martin Duplessis, Jae Young Ahn, Alexander W. Hird, Ryan E. Michael, Kiel Lazarski, Yanke Liang, Georg Jaeschke, Antonio Ricci, Annick Goergler, Daniel Rueher
  • SUBSTITUTED MACROCYCLIC INDOLE DERIVATIVES
    Publication number: 20230112244
    Abstract: The present invention relates to substituted macrocyclic indole derivatives of general formula (I): in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: September 8, 2022
    Publication date: April 13, 2023
    Inventors: Kai Thede, Anne Mengel, Clara Christ, Joachim Kuhnke, Sarah Anna Liesa Johannes, Philipp Buchgraber, Ulrich Klar, Ulrike Rauh, Stefan Kaulfuss, Amaury Ernesto Fernandez-Montalvan, Nicolas Werbeck, Ursula Moenning, Katrin Nowak-Reppel, Sven Wittrock, David McKinney, Michael H. Serrano-Wu, Chris Lemke, Mark Fitzgerald, Christopher Nasveschuk, Kiel Lazarski, Steven James Ferrara, Laura Furst, Guo Wei, Patrick Ryan McCarren, Rebecca Ann Harvey
  • SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
    Publication number: 20230095223
    Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.
    Type: Application
    Filed: November 11, 2021
    Publication date: March 30, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael
  • BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER
    Publication number: 20230024096
    Abstract: The invention provides bifunctional compounds of formula (I) or a pharmaceutically acceptable salt thereof. Formula (I). The compounds cause the degradation of SMARCA2 via the targeted ubiquination of SMARCA2 protein and subsequent proteasomal degradation and are thus useful for the treatment of cancer. The targeting ligand is of formula (TL).
    Type: Application
    Filed: October 28, 2020
    Publication date: January 26, 2023
    Inventors: Martin DUPLESSIS, Delphine GAUFRETEAU, Roman HUTTER, Eleonora JOVCHEVA, Bernd KUHN, Kiel LAZARSKI, Yanke LIANG, Thomas LUEBBERS, Laetitia Janine MARTIN, Rainer E. MARTIN, Barbara Johanna MUELLER, Roger NORCROSS, Philipp SCHMID, Jean-Yves WACH
  • BIFUNCTIONAL COMPOUNDS
    Publication number: 20230002367
    Abstract: The invention provides a bifunctional compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein said Targeting Ligand, Linker and Degron are as described herein.
    Type: Application
    Filed: October 26, 2020
    Publication date: January 5, 2023
    Inventors: Delphine GAUFRETEAU, Roman HUTTER, Eleonora JOVCHEVA, Bernd KUHN, Thomas LUEBBERS, Rainer E. MARTIN, Laetitia Janine MARTIN, Barbara Johanna MUELLER, Roger NORCROSS, Fabienne RICKLIN, Philipp SCHMID, Jean-Yves WACH, Juergen WICHMANN, Martin DUPLESSIS, Kiel LAZARSKI, Yanke LIANG
  • Degraders and Degrons for targeted protein degradation
    Patent number: 11524949
    Abstract: Pharmaceutical Degraders and Degrons for use in therapeutic applications are described herein.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: December 13, 2022
    Assignee: C4 Therapeutics, Inc.
    Inventors: Andrew J. Phillips, Christopher G. Nasveschuk, James A. Henderson, Minsheng He, Kiel Lazarski